Patents by Inventor Sheldon Cao

Sheldon Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIN MODULATOR
    Publication number: 20260152501
    Abstract: A cyclin modulator, specifically a compound of formula (I) or a pharmaceutically acceptable salt thereof are provided.
    Type: Application
    Filed: August 28, 2023
    Publication date: June 4, 2026
    Inventors: Sheldon CAO, Xiaolei WANG, Feng DING
  • GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases
    Patent number: 12516016
    Abstract: Provided herein are GPX4 inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 6, 2026
    Assignees: EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Sheldon Cao, Xiaolei Wang
  • Anti-HER2 antibody-drug conjugate and application thereof
    Patent number: 12318455
    Abstract: An anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate or a pharmaceutically acceptable salt thereof, and an application of the anti-HER2 antibody-drug conjugate for preparing an antitumor 5 pharmaceutical product.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: June 3, 2025
    Assignee: HANGZHOU ADCORIS BIOPHARMA CO., LTD.
    Inventors: Zhenwei Miao, Tong Zhu, B. Khasanov Alisher, Gang Chen, Zhaohui Li, Sheldon Cao
  • TARGETED PROTEASE DEGRADATION (TED) PLATFORM
    Publication number: 20250041306
    Abstract: A targeted protease degradation (TED) platform that can be a conjugate of target molecule-linker-E3 ligase ligand as shown in formula I, i.e., RT-L1-RE3, wherein RT is a monovalent group of the target molecule; RE3 is a monovalent group of the E3 ligase ligand; L1 is a linker linking A and B; and L1 is as shown in formula III below: —W1-L2-W2—(II).
    Type: Application
    Filed: October 9, 2022
    Publication date: February 6, 2025
    Inventors: Sheldon CAO, Xiaolei WANG
  • GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES
    Publication number: 20240246901
    Abstract: Provided herein are GPX4 inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition.
    Type: Application
    Filed: March 10, 2021
    Publication date: July 25, 2024
    Inventors: Sheldon Cao, Xiaolei Wang
  • GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
    Patent number: 11998534
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: June 4, 2024
    Assignee: Eubulus Biotherapeutics Inc.
    Inventor: Sheldon Cao
  • HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20240101546
    Abstract: Provided herein are heteroaryl-acetylene compounds, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of GPX4-mediated disorders, diseases, or conditions.
    Type: Application
    Filed: December 3, 2022
    Publication date: March 28, 2024
    Inventors: Sheldon Cao, Chaoran Huang, Xiaolie Wang
  • TARGETED PROTEASE DEGRADATION (TED) PLATFORM
    Publication number: 20230210999
    Abstract: The present invention relates to a targeted protease degradation (TED) platform, and specifically to a conjugate of target molecule-linker-E3 ligase ligand as shown in formula I, RT-L1-RE3 (formula I), wherein RT is a monovalent group of the target molecule, RE3 is a monovalent group of the E3 ligase ligand, L1 is the linker linking A and B, and L1 is as shown in formula II below: —W-L2-W2— (II).
    Type: Application
    Filed: April 9, 2021
    Publication date: July 6, 2023
    Inventors: Sheldon CAO, Xiaolei WANG, Chaoran HUANG
  • Anti-5T4 antibody-drug conjugate and use thereof
    Patent number: 11679162
    Abstract: Provided in the present invention is an anti-5T4 antibody-drug conjugate and the use thereof. In particular, provided in the present invention is an anti-5T4 antibody-drug conjugate. Also provided in the present invention are the pharmaceutical use of the anti-5T4 antibody-drug conjugate and the effect thereof in inhibiting or preventing tumors.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 20, 2023
    Assignee: HANGZHOU ADCORIS BIOPHARMA CO., LTD.
    Inventors: Zhenwei Miao, Tong Zhu, Alisher B. Khasanov, Sheldon Cao, Zhaohui Li, Min Wu
  • TARGETED PROTEASE DEGRADATION PLATFORM
    Publication number: 20210369853
    Abstract: Disclosed is a targeted protease degradation platform (TED), which in particular is a conjugate of target molecule-linker-E3 ligase ligand as shown in the structure of A-L1-B (formula I), wherein the A is the monovalent group of the target molecule, the B is the monovalent group of the E3 ligase ligand, the L1 is the linker linking A and B, and L1 is as shown in —X-L2-Y— (formula II).
    Type: Application
    Filed: October 9, 2019
    Publication date: December 2, 2021
    Inventors: Sheldon CAO, Xiaolei WANG, Chaoran HUANG
  • GPX4 INHIBITOR IN COMBINATION WITH ANTICANCER AGENT FOR TREATING PROLIFERATIVE DISEASE
    Publication number: 20210244715
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Inventor: Sheldon Cao
  • ANTI-5T4 ANTIBODY-DRUG CONJUGATE AND USE THEREOF
    Publication number: 20190374651
    Abstract: Provided in the present invention are an anti-5T4 antibody-drug conjugate and the use thereof. In particular, provided in the present invention is an anti-5T4 antibody-drug conjugate. Also provided in the present invention are the pharmaceutical use of the anti-5T4 antibody-drug conjugate and the effect thereof in inhibiting or preventing tumors.
    Type: Application
    Filed: January 8, 2018
    Publication date: December 12, 2019
    Inventors: Zhenwei MIAO, Tong ZHU, Alisher B. KHASANOV, Sheldon CAO, Zhaohui LI, Min WU
  • ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
    Publication number: 20190091345
    Abstract: An anti-HER2 antibody-drug conjugate or a pharmaceutically acceptable salt thereof, and an application of the anti-HER2 antibody-drug conjugate for preparing an antitumor pharmaceutical product.
    Type: Application
    Filed: February 4, 2017
    Publication date: March 28, 2019
    Inventors: Zhenwei MIAO, Tong ZHU, B. Khasanov ALISHER, Gang CHEN, Zhaohui LI, Sheldon CAO
  • Compounds and their methods of use
    Patent number: 10000479
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 19, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye
  • Small molecule compound and synthesizing method and uses thereof
    Patent number: 9920022
    Abstract: Provided is a small molecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth of the hairs, thus exhibiting an obvious effect of promoting hair growth. In addition, changes in the weight of a mouse in each group are slow, indicating that the test compound does not cause weight loss in an animal.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: March 20, 2018
    Assignee: TECHNODERMA MEDICINES PTE LTD.
    Inventors: Zengquan Wang, Sheldon Cao, Chen Mao
  • Therapeutically active compositions and their methods of use
    Patent number: 9856279
    Abstract: Provided are piperazine compounds of Formula I useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
    Publication number: 20170210749
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • SMALL MOLECULE COMPOUND AND SYNTHESIZING METHOD AND USES THEREOF
    Publication number: 20170158651
    Abstract: Provided is a small molecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth of the hairs, thus exhibiting an obvious effect of promoting hair growth. In addition, changes in the weight of a mouse in each group are slow, indicating that the test compound does not cause weight loss in an animal.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 8, 2017
    Inventors: Zengquan Wang, Sheldon Cao, Chen Mao
  • Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
    Patent number: 9662327
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 30, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20170137414
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 18, 2017
    Applicant: AGIOS Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye